Company

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis
HKG: 3696Insilico Medicine

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine (HKG: 3696), an AI‑powered drug discovery company, announced the nomination of ISM9546 as a preclinical candidate (PCC) – an innovative, oral, peripherally restricted VAV1 molecular glue degrader with…

Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCCancer

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer
CancerMarket approval filings

Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer

CancerClinical trial approval / initiation

OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors

Breakthrough therapyCancer

D3 Bio Secures Breakthrough Therapy Designation for Elisrasib – Next-Generation KRAS G12C Inhibitor for First-Line NSCLC

Show More